Stockreport

Pfenex: Update; Still A Buy For Their Therapeutic Proteins Platform [Seeking Alpha]

PFENEX INC  (PFNX) 
NASDAQ:AMEX Investor Relations: pfenex.com
PDF Summary PFNX has made much progress since my first article in May 2018, including the approval of their first bio-similar osteoporosis drug, PF 708 on Oct 7, 2019. PFNX [Read more]